Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akoya Biosciences, Inc. (AKYA)

11.8   -0.51 (-4.14%) 12-07 16:00
Open: 12.29 Pre. Close: 12.31
High: 12.52 Low: 11.73
Volume: 66,881 Market Cap: 448(M)

Technical analysis

as of: 2022-12-07 4:20:13 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.92     One year: 16.79
Support: Support1: 10.18    Support2: 8.47
Resistance: Resistance1: 12.77    Resistance2: 14.38
Pivot: 12.64
Moving Average: MA(5): 12.58     MA(20): 12.71
MA(100): 12.91     MA(250): 11.99
MACD: MACD(12,26): -0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 19.6     %D(3): 36.8
RSI: RSI(14): 39.9
52-week: High: 16.56  Low: 8.02
Average Vol(K): 3-Month: 127 (K)  10-Days: 211 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AKYA ] has closed below the lower bollinger band by 9.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ AKYA ] is to continue within current trading range. It is unclear right now based on current values. 46.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.54 - 12.63 12.63 - 12.69
Low: 11.51 - 11.62 11.62 - 11.71
Close: 11.64 - 11.8 11.8 - 11.91

Company Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Headline News

Wed, 07 Dec 2022
Turkish Navy's first Reis-class (Type 214TN) AIP submarine begins sea trials - Naval News

Tue, 06 Dec 2022
Akoya Biosciences, Inc. (NASDAQ:AKYA) Director Sells $14575.00 in Stock - MarketBeat

Mon, 28 Nov 2022
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Wed, 16 Nov 2022
This Insider Has Just Sold Shares In Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St

Wed, 09 Nov 2022
Further weakness as Akoya Biosciences (NASDAQ:AKYA) drops 16% this week, taking one-year losses to 12% - Simply Wall St

Thu, 03 Nov 2022
Akoya Biosciences (NASDAQ:AKYA) Receives New Coverage from Analysts at Capital One Financial - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Instruments & Supplies
Shares Out. 38 (M)
Shares Float 12 (M)
% Held by Insiders 12.6 (%)
% Held by Institutions 80.1 (%)
Shares Short 1,810 (K)
Shares Short P.Month 1,930 (K)

Stock Financials

EPS -1.45
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.98
Profit Margin (%) -99.5
Operating Margin (%) -93
Return on Assets (ttm) -21.9
Return on Equity (ttm) -65.4
Qtrly Rev. Growth 39.9
Gross Profit (p.s.) 0.9
Sales Per Share 1.83
EBITDA (p.s.) -1.54
Qtrly Earnings Growth 0
Operating Cash Flow -49 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -8.2
PEG Ratio 0
Price to Book value 5.95
Price to Sales 6.41
Price to Cash Flow -9.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.